XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PRODUCT REVENUE AND RESERVES FOR VARIABLE CONSIDERATION
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
PRODUCT REVENUE AND RESERVES FOR VARIABLE CONSIDERATION PRODUCT REVENUE AND RESERVES FOR VARIABLE CONSIDERATION
To date, the Company’s only source of product revenue has been from the U.S. sales of Auryxia. Total net product revenue was $31.0 million and $34.7 million for the three months ended March 31, 2024 and 2023, respectively. Product revenue allowance and reserve categories were as follows: 
(in thousands)Chargebacks
and Discounts		Rebates, Fees
and other
Deductions		Product ReturnsTotal
Balance at December 31, 2023$1,607 $22,991 $6,916 $31,514 
Current provisions related to sales in current year1,910 10,229 961 13,100 
Adjustments related to prior year sales(93)(1,374)(105)(1,572)
Credits/payments made(2,216)(18,282)(1,974)(22,472)
Balance at March 31, 2024$1,208 $13,564 $5,798 $20,570 
(in thousands)Chargebacks
and Discounts		Rebates, Fees
and other
Deductions		Product ReturnsTotal
Balance at December 31, 2022$1,259 $26,252 $10,923 $38,434 
Current provisions related to sales in current year1,709 17,477 1,302 20,488 
Adjustments related to prior year sales(483)(1,266)(231)(1,980)
Credits/payments made(1,997)(22,321)(1,631)(25,949)
Balance at March 31, 2023$488 $20,142 $10,363 $30,993 
Chargebacks, discounts and estimated product returns are recorded as a reduction of revenue in the period the related product revenue is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Chargebacks are recorded as a reduction to accounts receivable while discounts, rebates, fees and other deductions are recorded with a corresponding increase to accrued expenses and other current liabilities or accounts payable on the condensed consolidated balance sheets. Estimated product returns on product sales that are not expected to be returned within one year are recorded as other long-term liabilities in the condensed consolidated balance sheets.
Accounts receivable, net related to product sales, was approximately $23.9 million and $35.9 million as of March 31, 2024 and December 31, 2023, respectively.